Neuway, a biotech specializing in the delivery of mRNA and other biotherapeutic drug molecules to the CNS and other tissues via its proprietary EnPC drug-delivery technology, has announced two new appointments in its senior leadership team.
Dr Oliver Ernst, formerly Neuway’s Chief Operating Officer, has been promoted to Chief Executive Officer, and Dr Thomas Christoph has been appointed as new Chief Development Officer.
Dr Ernst, who joined Neuway in 2019 as Chief Operating Officer and Managing Director, will now lead the company as CEO. Ernst steps up to the role at a time where the company is ‘rapidly generating highly promising data, advancing our EnPC development program and entering into new partnerships’.
Neuway co-founder Dr. Heiko Manninga will continue to serve in his existing role as Chief Scientific Officer and Managing Director.
Meanwhile, Dr Christoph brings with him his experience a board certified pharmacologist with more than 25 years of experience in the pharmaceutical industry, led pharmacology and preclinical development teams at German pharmaceutical company Gruenenthal for many years. He has most recently served as a consultant for several biotech companies specializing in translational pharmacology.